Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5913964 | 0.86 | MAPK8 (0.44) | TP53ALOX15MAPK1CASP1CASP7 | |
| SCHEMBL5914134 | 0.77 | MAPK8 (0.44) | USP30 | |
| SCHEMBL29501428 | 0.77 | GRIN2B (0.50) | VCPCYP11B2GRIN2B | |
| SCHEMBL5914206 | 0.75 | MAPK8 (0.41) | — | |
| SCHEMBL5914214 | 0.75 | MAPK8 (0.41) | — | |
| SCHEMBL3646509 | 0.74 | CYP11B2 (0.74) | VCPCYP11B2GRIN2BBTKUSP30 | |
| SCHEMBL5266019 | 0.74 | MAPK8 (0.54) | — | |
| SCHEMBL30443744 | 0.73 | GRIN2B (0.50) | CYP11B2GRIN2BBTK | |
| SCHEMBL5914448 | 0.73 | CIT (0.44) | MAPK1 | |
| SCHEMBL5913876 | 0.73 | TAAR1 (0.46) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | VCP 1567/4885CYP11B2 333/4885GRIN2B 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.